Oxytocin levels in individuals with schizophrenia are high in cerebrospinal fluid but low in serum: A systematic review and meta-analysis

Oxytocin and Schizophrenia

Yazmín Hernández-Díaz · Thelma Beatriz González-Castro · Carlos Alfonso Tovilla-Zárate · María Lilia López-Narváez · Alma Delia Genis-Mendoza · Rosa Giannina Castillo-Avila · Miguel Ángel Ramos-Méndez · Isela Esther Juárez-Rojop

Received: 22 February 2021 / Accepted: 28 August 2021 / Published online: 8 September 2021
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021

Abstract
Schizophrenia is a debilitating mental illness. Levels of oxytocin have been proposed as a biomarker of schizophrenia; however, the observed levels of oxytocin in individuals with schizophrenia have been inconsistent across studies. We performed a meta-analysis to evaluate oxytocin levels in plasma, serum and cerebrospinal fluid to see if there are statistically different concentrations between individuals with schizophrenia and the comparison group. The meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Following the inclusion and exclusion criteria, 14 studies were included in the meta-analysis. The quality of the study was evaluated by the Newcastle–Ottawa Scale (NOS). A random-effects model was performed using the Comprehensive Meta-analysis software with the standardized mean difference (SMD) and 95% confidence intervals (CIs). Serum oxytocin levels in individuals with schizophrenia were significantly lower than that in comparison group (SMD = −1.74, 95% CI = −3.22 to −0.26, p = 0.02) but cerebrospinal fluid oxytocin levels in individuals with schizophrenia were significantly higher than those in the comparison group (SMD = 0.55, 95% CI = 0.05 to 1.04, p = 0.03). Our results suggest that oxytocin levels in cerebrospinal fluid are increased in individuals with schizophrenia but decreased in serum. Therefore, the oxytocin system dysregulation may play a role in the pathophysiology of schizophrenia and it should be measured in more populations for a possible implementation as a biomarker of schizophrenia.

Keywords Oxytocin · Schizophrenia · serum · Cerebrospinal fluid

Introduction
There are numerous environmental, biological and genetic factors that interact and contribute to the vulnerability or resilience to develop schizophrenia (SCZ). Schizophrenia is a devastating mental illness; it is highly heritable, chronic, severe and disabling. Schizophrenia is characterized by positive, negative and cognitive symptoms. Positive symptoms consist of psychotic symptoms such as hallucinations, delusions that are often paranoid, as well as disorganized speech and behavior. Negative symptoms include flattened affect, poverty of speech, loss of a sense of pleasure and loss of interests and drive; while cognitive symptoms comprise deficits in attention, working memory, and in executive functions (Owen et al., 2016; Perkovic et al., 2017). Onset symptoms of schizophrenia typically occur in early adult life and occur earlier in men than in women (Nadeem et al., 2004; Schultz et al., 2007). The etiology of SCZ is multifactorial and reflects an interaction between genetic and environmental contributors. Some risk factors include family history, social isolation, urbanicity, pregnancy and birth complications, acute life events, developmental difficulties, central nervous system infections in childhood and substance abuse (Stilo and Murray, 2019; Wahlberg et al., 2004).
New antipsychotic medications have been introduced for the schizophrenia treatment; however, the management of this disease remains a substantial clinical challenge. Patients should be treated early and optimally with antipsychotic agents, however, sometimes patient does not respond to or cannot tolerate standard therapy, therefore, combination therapy is often required. For patients with inadequate response in target psychotic or schizophrenia symptoms, adding a second antipsychotic medication has yielded largely negative results based on randomized trials (Ng et al., 2021).

Nowadays, biomarkers and indicators of schizophrenia diagnosis or the severity of the disease are highly necessary. Biomarkers that can be easily available are body fluids that could help in the (1) diagnostic, (2) prognostic, or (3) prediction of individual response to a particular therapy (theranostics) (Weickert et al., 2013). Many biomarkers have been proposed in schizophrenia (Liu et al., 2021), including oxytocin.

Oxytocin (Oxt) is a neuropeptide synthesized primarily in neurons of the hypothalamic supraoptic and paraventricular nuclei. The Oxt system is involved in the neuromodulation of social behaviors, affiliative behaviors and aggression. Altered levels of Oxt have been reported in individuals with SCZ; therefore, the Oxt system could be linked to the pathophysiology of schizophrenia (Aydin et al., 2019; Goldman et al., 2008; Rubin et al., 2010).

Up to today, the mechanism concerning the effect of oxytocin as a risk factor for developing SCZ is unknown. However, many association studies have shown that individuals with schizophrenia have decreased levels of Oxt. Therefore, the aim of this systematic review and meta-analysis of case–control studies was to evaluate the effect of Oxt levels on individuals with schizophrenia and to explore differences in Oxt levels between individuals with SCZ and healthy subjects. Additionally, we examined effects of potential confounding factors that may have an impact on these relationships.

Materials and Methods

Data sources and search strategy

The electronic databases PubMed, Scopus and EBSCO were searched for articles. The keywords used in the databases were: “oxytocin level” AND “schizophrenia”. More specifically, the search details specified in PubMed were: (“oxytocin level” [MeSH Terms] OR “oxytocin level” [All Fields] OR “plasma oxytocin” [All Fields] OR “serum oxytocin” [All Fields] OR “CSF oxytocin” [All Fields]) AND (“schizophrenia” [MeSH Terms] OR “schizophrenia” [All Fields] OR “schizophrenia spectrum disorders” [All Fields]). The reference lists of the retrieved articles were then reviewed to identify additional studies. The protocol for this systematic review and meta-analysis was registered in PROSPERO (CRD42020221590) and can be accessed on: (https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=221590). The meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. We restricted the search to studies in humans published in English.

Study selection

In this systematic review we included studies that evaluated oxytocin concentrations in individuals with schizophrenia; these studies had to fulfill the following criteria: (1) studied individuals diagnosed with schizophrenia spectrum disorders; (2) the study design had to be a case–control study that reported values in mean and standard deviation of oxytocin levels or had enough data to calculate these values; (3) compared the levels of oxytocin between two groups of individuals, those with SCZ and a healthy control group, and (4) publications in peer-reviewed journals.

The following type of studies were excluded: (1) reviews, case reports, case-only studies, animal studies, and simple commentaries; (2) overlapping publications and (3) publications lacking measures of Oxt levels.

The selection process was independently completed by our research team and any discrepancy or disagreement was resolved by discussion until consensus was reached among the reviewers.

Data extraction, assessment of quality and risk of bias

Two authors (YHD and TBGC) extracted data using a structured form not blinded to study results, author names or institutions. This form included study data and participants description. The methodological quality and risk of bias of included studies was evaluated by two investigators (YHD and TBGC). Disagreements were resolved by a third reviewer (CATZ). The Newcastle–Ottawa (NOS) quality scale consists of three parts: selection, comparability and exposure assessment. High-quality response earns a point, totaling up to nine points (the comparability question earns up to two points). The total is calculated by adding the points of all categories. In our meta-analysis, we considered 6 points or higher as a good-quality study. The risk of bias assessment was performed using the ROBINS-I scale that evaluates the risk of bias in "Low risk", "Moderate risk", "High risk", "Critical risk" in seven domains of ROBINS-I criteria.
Statistical analysis

The Comprehensive Meta-analysis version 2 (Biostat, Englewood, NJ, USA) software was used to deal with quantitative data. Standardized mean differences (SMD) were calculated and represented the differences in the mean oxytocin levels between individuals with SCZ and healthy controls; with 95% confidence intervals (CI) and were illustrated by forest plots.

Heterogeneity was evaluated by Q-test and $I^2$-test. Generally, if $p < 0.05$ (Q-test) or $I^2$-test $> 50\%$, when heterogeneity was thought to exist, the random-effect models was used. Heterogeneity is the systematic difference between the results of the studies that cannot be attributed simply to chance. We analyzed subgroups of studies to examine the source of potential heterogeneity based on the region, analytical methods and gender.

Potential publication bias was explored by using funnel plot and Egger line regression test (Egger's test). Sensitivity analyses were conducted to evaluate the stability of pooled results. All tests were two-sided and a p value of < 0.05 was considered statistically significant.

Results

Systematic review

The PRISMA flow diagram of the study selection used in this meta-analysis is shown in Fig. 1. A total of 309 articles associated with the searched keywords were first identified. Of these articles, 145 were excluded based on the titles and key words; the full texts of 164 studies were obtained and 147 more papers were eliminated. Eventually, 17 studies were enrolled in this systematic review (Aydın et al., 2019; Beckmann et al., 1985; Glovinsky et al., 1994; Goldman et al., 2008; Guzel et al., 2018; Jobst et al., 2014; Kéri et al., 2009; Liu et al., 2019; Rubin et al., 2014, 2013, 2010, 2018; Sasayama et al., 2012; Speck et al., 2019; Strauss et al., 2019, 2015; Walss-Bass et al., 2013).

The characteristics of the seventeen selected studies are presented in Table 1. All the studies were published between 1985 and 2019. Eight studies were conducted in the United States, three in Germany, two in Turkey, one in Japan, one in Hungary, one in Portugal and one in China.
Table 1 Characteristics of the studies included in the meta-analysis

| Author          | Year | Country | Assay method | Time sampling | Duration of illness (years) mean | Cases N | Cases Age mean males | Controls N | Controls Age mean males | Oxytocin (pg/ml) Mean SD | Oxytocin (pg/ml) Mean SD |
|-----------------|------|---------|--------------|---------------|----------------------------------|---------|-----------------------|-------------|-------------------------|------------------------|------------------------|
| Goldman, M.     | 2008 | USA     | RIA          | Evening       | 17.5                             | 15      | 40.8                  | 9           | 222.33                  | 227.33                 | 7 34.7 4                   | 240 224                |
| Walss-Bass, C.  | 2013 | Portugal| ELISA        | -             | -                                | 60      | 42.1                  | 45          | 308.04                  | 136.99                 | 20 39.6 14                | 199.33 119.42           |
| Strauss, G. P.  | 2015 | USA     | RIA          | -             | -                                | 40      | 43.7                  | 28          | 24.46                   | 7.54                   | 22 43.1 14                | 19.66 5.86              |
| Aydin, O.       | 2019 | Turkey  | ELISA        | Morning       | 10.55                            | 34      | 30                    | 22          | 300.46                  | 130.21                 | 31 29.6 13                | 609.89 217.72           |
| Strauss, G. P.  | 2019 | USA     | RIA          | -             | -                                | 30      | 46.6                  | 22          | 9.93                    | 5.06                   | 21 42.5 8                 | 16.64 7.08              |
| Speck, L. G.    | 2019 | Germany | RIA          | -             | 12.4                             | 35      | 40.4                  | 23          | 4.59                    | 3.35                   | 35 36 23                  | 5.48 4.5                |
| Serum           |      |         |              |               |                                  |         |                       |             |                         |                        |                        |                        |
| Rubin, L. H.   | 2010 | USA     | RIA          | -             | 12.2                             | 50      | 30.92                 | 27          | 286.48                  | 210.44                 | 58 27.74 27                | 312.48 203.07           |
| Rubin, L. H.   | 2013 | USA     | ELISA        | -             | -                                | 38      | 24.3                  | 24          | 356.8                   | 242.22                 | 38 28 24                 | 385.13 238.15           |
| Guzel, D.       | 2018 | Turkey  | ELISA        | -             | 163.6                            | 34      | 38.9                  | 34          | 12.95                   | 4.84                   | 24 40.7 24                | 35.41 12.75             |
| Rubin, L. H.   | 2018 | USA     | ELISA        | Morning       | -                                | 35      | 39                    | 23          | 5.95                    | 0.7                    | 60 32.6 24                | 6.1 0.8                 |
| Liu, Y.         | 2019 | China   | ELISA        | Morning       | -                                | 52      | 20.7                  | 31          | 518.96                  | 22.22                  | 41 22.1 23                | 711.58 40.57            |
| Cerebro-spinal fluid |      |         |              |               |                                  |         |                       |             |                         |                        |                        |                        |
| Beckmann, H.    | 1985 | Germany | RIA          | Morning       | 7.2                              | 28      | 30.6                  | 28          | 11.74                   | 4.99                   | 16 35 13                  | 7.11 4.03               |
| Glovinsky, D.   | 1994 | USA     | RIA          | Morning       | -                                | 40      | 29                    | 31          | 9.31                    | 4.34                   | 15 30 10                  | 8.92 3.01               |
| Sasayama, D.    | 2012 | Japan   | ELISA        | -             | 16.3                             | 27      | 42.6                  | -           | 10.52                   | 4.66                   | 21 38.3 -                 | 8.01 3.52               |
| Systematic review |      |         |              |               |                                  |         |                       |             |                         |                        |                        |                        |
| Keri, S.        | 2009 | Hungary | ELISA        | Morning       | -                                | 50      | 47.9                  | 16          | -                      | -                      | 50 47.8 16                | - -                     |
| Jobst, A.       | 2014 | Germany | ELISA        | Morning       | 6                                | 41      | 24.9                  | 41          | -                      | -                      | 45 24.6 45                | - -                     |
| Rubin, L. H.   | 2014 | USA     | ELISA        | Morning       | -                                | 57      | 35.3                  | 35          | -                      | -                      | 66 37.1 28                | - -                     |

ELISA: Enzyme-linked immunosorbent assay. RIA: radioimmunoassay
The sample sizes ranged from 15 to 60 in individuals with schizophrenia and from 7 to 66 in controls. Enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA) methods were implemented for the detection of Oxt levels. We identified three different biomaterials used for Oxt assays: plasma, serum and cerebrospinal fluid (CSF). Therefore, three meta-analysis were carried out, additionally, subgroup analyses were performed for each one of them based on data availability.

Study-specific quality is summarized in Fig. 2. All studies were awarded ≥ 7 points and were defined as good-quality studies according to NOS scale. The risk of bias was evaluated using the ROBINS-I tool. It was found that overall, a low risk of bias was obtained in 65% of the included studies (Fig. 3).

### Meta-analysis of plasma oxytocin levels in SCZ

First, the analysis included 214 individuals with schizophrenia and 136 individuals in the comparison group. In this analysis six studies were included (Aydin et al., 2019; Goldman et al., 2008; Speck et al., 2019; Strauss et al., 2019, 2015; Walss-Bass et al., 2013) (Table 1). The meta-analysis suggested no statistical differences between plasma oxytocin levels between individuals with schizophrenia and the comparison group (SMD = -0.27, 95% CI: -1.10 to 0.55 Pg/mL, \( p = 0.51, \) \( \text{I}^2 = 71, p(\text{Q}) < 0.01 \) (Table 2).

### Meta-analysis of serum oxytocin levels in SCZ

Second, we evaluated oxytocin levels in serum and found that these values were lower in cases than in the control group. This meta-analysis included five studies with 209 individuals with schizophrenia and 221 individuals in the comparison group (Guzel et al., 2018; Liu et al., 2019; Rubin et al., 2013, 2010, 2018). Table 1. The meta-analysis showed that serum oxytocin levels in SCZ individuals were significantly lower than in the comparison group (SMD = -1.74, 95% CI = -3.22 to -0.26 Pg/mL, \( p = 0.02, \) \( \text{I}^2 = 77, p(\text{Q}) < 0.01 \) (Table 2 and Fig. 3).

The results of the subgroup analysis are shown in Table 2. The method of evaluation (ELISA) showed a significant association of decreased oxytocin levels in individuals with schizophrenia. Other subgroups did not show statistical differences (Table 2).

### Meta-analysis of CSF oxytocin levels in SCZ

Finally, a third meta-analysis was conducted using three studies (Beckmann et al., 1985; Glovinsky et al., 1994; Sasayama et al., 2012) comprising 95 individuals with schizophrenia and 52 individuals in the comparison group (Table 1). The results of the meta-analysis indicated that cerebro-spinal fluid oxytocin levels in individuals with schizophrenia were significantly higher than in individuals of the comparison group (SMD = 0.55, 95% CI = 0.05 to 1.04, \( p = 0.03, \) \( \text{I}^2 = 50\% , p(\text{Q}) = 0.03 \).

### Meta-regression analyses

The following covariates were considered for meta-regression: mean age and gender. The results showed that mean age contributed to effect in the meta-analysis (Plasma, slope = -4.38, 95%CI = -6.24; -2.53, \( p = 0.001 \) and Serum, slope = -1.98, 95%CI = -3.11; -0.84, \( p = 0.006 \). The meta-regression model also showed significant results in the analysis by gender (Plasma, slope = -1.77, 95%CI = -2.45; -1.10, \( p = 0.001 \) and Serum, slope = 6.90, 95%CI = 5.20; 8.61, \( p = 0.001 \)).
Sensitivity analysis and publication bias

The sensitivity analysis indicated that the exclusion of none of the primary studies influenced the pooled estimates. For publication bias, the funnel plot was symmetric (Fig. 4). Moreover, Egger’s tests did not reveal significant evidence of publication bias among the included studies (Table 2 and Fig. 5).
Discussion

A biomarker refers to a molecular change in body tissues and fluids that can be used as a clinical indicator of a disease; in this case, the biomarker will allow better diagnostic procedures and therapeutic strategies in individuals with schizophrenia (Perkovic et al., 2017; Vargas, 2014).

The use of biomarkers that can be measured or determined from easily available body fluids such as serum or cerebrospinal fluid is highly recommended. As oxytocin acts centrally within the brain to control behavior, it has been suggested as biomarker of mental disorders. Oxytocin is a highly conserved neuropeptide produced in the hypothalamus, it has modulatory effects on a variety of social and non-social behaviors such as affiliation, stress, memory...
and learning (Churchland and Winkielman, 2012; Jones et al., 2017).

In the meta-analysis, we included fourteen studies that comprised 518 cases and 409 controls. Interestingly, we found that Oxt levels were lower in serum samples of individuals with SCZ but higher in CSF samples of individuals with SCZ.

A possible explanation for the increased Oxt levels in patients with schizophrenia could be that the release of Oxt contributes to the modulation and maintenance of other hormones such as cortisol, which could increase the response to the stressful stimuli (Donadon et al., 2018; Liu et al., 2019). Then, stressful experiences might alter the functioning of the suprachiasmatic nucleus altering the release of endogenous Oxt (Donadon et al., 2018; Liu et al., 2019). On the other hand, it has been proposed that low levels of serum oxytocin in individuals with acute schizophrenia are associated with the functionality of the patient, the severity of the disease and with the severity of the positive symptoms (Guzel et al., 2018). This could explain the contrasting observations regarding oxytocin concentrations in the central system (high in schizophrenia) and in blood (low in schizophrenia); nevertheless, more studies are necessary in order to confirm and understand what causes those differences. As we observed in our meta-analysis, oxytocin concentrations in cerebrospinal fluid indicated that were significantly higher in individuals with schizophrenia than in controls. Beckmann et al. (Beckmann et al., 1985) reported increased concentrations of oxytocin in schizophrenic patients, and they were higher in those receiving neuroleptic treatment. In addition, oxytocin concentrations increased after three weeks of neuroleptic treatment. However, another study did not fully support these results (Sasayama et al., 2012); therefore, more data are required to fully explore this relationship.

In our meta-analysis we evaluated several confounding factors in order to identify those that could impact the relationship between Oxt levels and SCZ. For instance, different analytical methods to measure oxytocin concentrations were used among the studies. Subgroup analyses revealed that Oxt levels were significantly lower in patients with SCZ compared to controls when the concentrations were measured through ELISA; suggesting that ELISA assays may have been more sensitive in detecting Oxt levels. However, blood based biomarkers as oxytocin has high specificity and sensitivity in distinguishing SCZ patients from healthy controls, moreover, cerebrospinal fluid Oxt allow the analysis of biochemical changes that reflect pharmacological activity and this may be clinical accessibility in the living patient (Harris et al., 2012; Wan et al., 2012).

Our study had some advantages. First, the sensitivity analyses indicated that the removal of individual studies did not alter the final results, which increased the robustness of our conclusions. Second, no significant publication bias was detected, suggesting that the results are also reliable. On the other hand, our meta-analysis also presents some limitations. Firstly, the number of studies included was small and stratified analyses might have lower power to identify potential confounding factors. Secondly, there was significant heterogeneity in this analysis, which may have affected the precision of the overall results. Thirdly, we observed opposing patterns of findings observed for serum vs. CSF. This is important, because according the source and origin of oxytocin, its mechanism can be different. Finally, the present meta-analysis focused only on studies published in English, the ones reported in other languages might have changed the present results.

The results of this meta-analysis could be potentially very relevant for patients and health care providers due to that the oxytocin system is regarded as being of relevance for social interaction. Several researches suggest that the Oxt system may play a role in regulating the expression of schizophrenia-spectrum disorders. Studies have identified that Oxt levels are associated with more severe symptoms in all three domains of SCZ. Respect to cognition, Oxt levels have been associated with enhanced social cognition including more prosocial behavior and superior emotion recognition (Feifel et al., 2016; Shilling and Feifel, 2016). Evidence for a relationship between Oxt levels and symptom suggests that Oxt may contribute to the etiology of SCZ, therefore, targeting the central Oxt system may yield novel treatments to address these symptoms, moreover, can contribute to diagnostic and prognostic to this disease improving the quality of life in patients with schizophrenia and decrease health costs worldwide (Ng et al., 2021).

Conclusions

In summary, the present meta-analysis found increased levels oxytocin in CSF but decreased levels of oxytocin in serum. These results suggest that the oxytocin system dysregulation may play a role in the pathophysiology of schizophrenia. Oxt could be an interesting candidate in the search for biomarkers that could improve diagnosis and evaluation of patients with schizophrenia. Nonetheless, more well-designed and large-scale studies are needed to
continue investigating the mechanisms and mediating factors for these findings.

Author contributions YHD, TBGC, CATZ and IEJR participated in planning the study, data analysis, and drafting the manuscript. RGCA and MARM assisted and helped in all analysis. MLLN and ADGM supervised the study, participated in data analysis, and drafted the manuscript.

Data availability Data is available upon request.

Declarations

Ethical approval This article does not contain any studies with human participants performed by any of the authors.

Conflicts of interest All the authors declare no conflict of interest.

References

Aydin O, Baltıkçı K, Taş C, Ünal-Aydın P, Taneli F, Esen-Danacı A (2019) Assessing the relationship between attachment, parental attitude and plasma oxytocin in schizophrenia patients and their unaffected siblings. Nord J Psychiatry 73:51–57

Beckmann H, Lang RE, Gattaz WF (1985) Vasopressin–oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. Psychoneuroendocrinology 10:187–191

Churchland PS, Winkielman P (2012) Modulating social behavior with oxytocin: how does it work? What does it mean? Horm Behav 61:392–399

Donadon MF, Martin-Santos R, Osório FL (2018) The Associations Between Oxytocin and Trauma in Humans: A Systematic Review. Front Pharmacol 9:154

Feifel D, Shilling PD, MacDonald K (2016) A Review of Oxytocin’s Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia. Biol Psychiatry 79:222–233

Glovinsky D, Kalogeras KT, Kirch DG, Suddath R, Wyatt RJ (1994) Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication. Schizophr Res 11:273–276

Goldman M, Marlow-O’Connor M, Torres I, Carter CS (2008) Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr Res 98:247–255

Guzel D, Yazici AB, Pek TM, Doganay S, Simsek ABS, Saglam K, Turan C, Yazici E (2018) Atrial natriuretic peptide and posterior pituitary neurohormone changes in patients with acute schizophrenia. Neuropsychiatr Dis Treat 14:1855–1860

Harris LW, Pietsch S, Cheng TM, Schwarz E, Guest PC, Bahn S (2012) Comparison of peripheral and central schizophrenia biomarker profiles. PLoS one 7:e46368

Jobst A, Dehning S, Ruf S, Notz T, Buchheim A, Henning-Fast K, Meißner D, Meyer S, Bondy B, Müller N, Zill P (2014) Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenic patients. Acta Neuropsychiatr 26:347–355

Jones C, Barrera I, Brothers S, Ring R, Wahlestedt C (2017) Oxytocin and social functioning. Dialogues Clin Neurosci 19:193–201

Kéri S, Kiss I, Kelemen O (2009) Sharing secrets: oxytocin and trust in schizophrenia. Soc Neurosci 4:287–293

Liu, Y., Song, X., Liu, X., Pu, J., Gui, S., Xu, S., Tian, L., Zhong, X., Zhao, L., Wang, H., Liu, L., Xu, G., Xie, P., 2021. Alteration of lipids and amino acids in plasma distinguish schizophrenia patients from controls: a targeted metabolomics study. Psychiatry and clinical neurosciences.

Liu Y, Tao H, Yang X, Huang K, Zhang X, Li C (2019) Decreased Serum Oxytocin and Increased Homocysteine in First-Episode Schizophrenia Patients. Front Psychiatry 10:217

Nadeem Z, McIntosh A, Lawrie S (2004) Schizophrenia. Evid Based Ment Health 7:2–3

Ng QX, Chong JWX, Chee KT (2021) Add-on pharmacotherapy for patients with first-episode schizophrenia: a clinical perspective. Eur J Clin Pharmacol 77:931–932

Owen MJ, Sawa A, Mortensen PB (2016) Schizophrenia Lancet 388:86–97

Perkovic, M.N., Erjavec, G.N., Strac, D.S., Uzun, S., Kozumplik, O., Pivac, N., 2017. Theranostic Biomarkers for Schizophrenia. Int J Mol Sci 18.

Rubin LH, Carter CS, Bishop JR, Pournaajafi-Nazarloo H, Drogos LL, Hill SK, Ruocco AC, Keedy SK, Reilly JL, Keshavan MS, Pearlsong GD, Tammenga CA, Gershon ES, Sweeney JA (2014) Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophr Bull 40:1374–1384

Rubin LH, Carter CS, Bishop JR, Pournaajafi-Nazarloo H, Harris MS, Hill SK, Reilly JL, Sweeney JA (2013) Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis. Schizophr Res 146:138–143

Rubin LH, Carter CS, Drogos L, Pournaajafi-Nazarloo H, Sweeney JA, Maki PM (2010) Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res 124:13–21

Rubin LH, Li S, Yao L, Keedy SK, Reilly JL, Hill SK, Bishop JR, Sue Carter C, Pournaajafi-Nazarloo H, Drogos LL, Gershon E, Pearlsong GD, Tammenga CA, Clementz BA, Keshavan MS, Liu S, Sweeney JA (2018) Peripheral oxytocin and vasopressin modulates regional brain activity differently in men and women with schizophrenia. Schizophr Res 202:173–179

Sasayama D, Hattori K, Teraishi T, Hori O, Ota M, Yoshida S, Arima K, Higuchi T, Amano N, Kunugi H (2012) Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. Schizophr Res 139:201–206

Schultz SH, North SW, Shields CG (2007) Schizophrenia: a review. Am Fam Physician 75:1821–1829

Shilling PD, Feifel D (2016) Potential of Oxytocin in the Treatment of Schizophrenia. CNS Drugs 30:193–208

Speer LG, Schöner J, Birmwold F, Heinz A, Gallinat J, Majic T, Montag C (2019) Endogenous oxytocin response to film scenes of attachment and loss is pronounced in schizophrenia. Soc Cogn Affect Neurosci 14:109–117

Stillo SA, Murray RM (2019) Non-Genetic Factors in Schizophrenia. Curr Psychiatry Rep 21:100

Strauss GP, Chapman HC, Keller WR, Koenig JI, Gold JM, Carpenter WT, Buchanan RW (2019) Endogenous oxytocin levels are associated with impaired social cognition and neurocognition in schizophrenia. J Psychiatr Res 112:38–43

Strauss GP, Keller WR, Koenig JI, Gold JM, Frost KH, Buchanan RW (2015) Plasma oxytocin levels predict social cue recognition in individuals with schizophrenia. Schizophr Res 162:47–51

Vargas G (2014) Biomarkers in Schizophrenia Biomark Med 8:1–3

Wahlberg KE, Wynne LC, Hakko H, Läksy K, Morig J, Miettunen J, Tienari P (2004) Interaction of genetic risk and adoptive parent communication deviance: longitudinal prediction of adoptee psychiatric disorders. Psychol Med 34:1531–1541

Walss-Bass C, Fernandes JM, Roberts DL, Service H, Velligan D (2013) Differential correlations between plasma oxytocin and...
social cognitive capacity and bias in schizophrenia. Schizophr Res 147:387–392
Wan HI, Soares H, Waring JF (2012) Use of cerebrospinal fluid biomarkers in clinical trials for schizophrenia and depression. Biomark Med 6:119–129
Weickert CS, Weickert TW, Pillai A, Buckley PF (2013) Biomarkers in schizophrenia: a brief conceptual consideration. Dis Markers 35:3–9

Authors and Affiliations

Yazmín Hernández-Díaz¹ · Thelma Beatriz González-Castro¹ · Carlos Alfonso Tovilla-Zárate² · María Lilia López-Narváez³ · Alma Delia Genis-Mendoza⁴ · Rosa Giannina Castillo-Avila⁵ · Miguel Ángel Ramos-Méndez⁵ · Isela Esther Juárez-Rojop⁵

Yazmín Hernández-Díaz yazmin.hdez.diaz@gmail.com
Thelma Beatriz González-Castro thelma.glez.castro@gmail.com
María Lilia López-Narváez dralilialonar@yahoo.com.mx
Alma Delia Genis-Mendoza adgenis@inmegen.gob.mx
Rosa Giannina Castillo-Avila chispa_yhd@hotmail.com
Miguel Ángel Ramos-Méndez angel_mar@live.com.mx
Isela Esther Juárez-Rojop iselajuarezrojop@hotmail.com

¹ División Académica Multidisciplinaria de Jalpa de Méndez, Universidad Juárez Autónoma de Tabasco, Jalpa de Méndez, Tabasco, México
² División Académica Multidisciplinaria de Comalcalco, Universidad Juárez Autónoma de Tabasco, Comalcalco, Tabasco, México
³ Hospital General de Yajalón, Secretaría de Salud, Yajalón, Chiapas, México
⁴ Laboratorio de Genómica de Enfermedades Psiquiátricas y Neurodegenerativas, Instituto Nacional de Medicina Genómica, Ciudad de México, México
⁵ División Académica de Ciencias de La Salud, Universidad Juárez Autónoma de Tabasco, Villahermosa, Tabasco, México

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.